CIK 0002070849 · Non-accelerated filer<br>Emerging growth company
BillionToOne, Inc.
Sign in to watch- Ticker
- BLLN
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811082020
- Phone
- 650-460-2551
- Business address
- 1035 O'BRIEN DRIVE, MENLO PARK, CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $26,737,121
- in 19 filings, $26.7M under 10b5-1 plans
Net −$26,737,121. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-28 | Atay Oguzhan Chairman and CEO | Option exercise 10b5-1 | +8,333 | $2.80 | $23K | 8,333 |
| 2026-09-28 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −8,333 | $120.64 | $1.0M | 0 |
| 2026-09-28 | Atay Oguzhan Chairman and CEO | Sale 10b5-1 | −2,666 | $120.64 | $322K | 154,502 |
| 2026-09-28 | Atay Oguzhan Chairman and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −8,333 | $2.80 | $23K | 493,629 |
| 2026-09-24 | Tsao David Chief Technology Officer | Option exercise 10b5-1 | +3,333 | $2.80 | $9K | 4,333 |
| 2026-09-24 | Tsao David Chief Technology Officer | Sale 10b5-1 | −3,333 | $125.00 | $417K | 1,000 |
| 2026-09-24 | Tsao David Chief Technology Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −3,333 | $2.80 | $9K | 556,667 |
| 2026-09-24 | ten Bosch John Roderick SVP of Laboratory Operations | Sale 10b5-1 | −1,416 | $120.00 | $170K | 22,219 |
| 2026-09-21 | ten Bosch John Roderick SVP of Laboratory Operations | Sale 10b5-1 | −1,416 | $106.61 | $151K | 23,635 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Option exercise 10b5-1 | +19,384 | $8.65 | $168K | 20,084 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Option exercise 10b5-1 | +6,968 | $11.55 | $80K | 27,052 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Option exercise 10b5-1 | +2,920 | $17.12 | $50K | 29,972 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Option exercise 10b5-1 | +5,840 | $30.78 | $180K | 35,812 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Sale 10b5-1 | −19,384 | $110.36 | $2.1M | 16,428 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Sale 10b5-1 | −6,968 | $110.30 | $769K | 9,460 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Sale 10b5-1 | −2,920 | $110.31 | $322K | 6,540 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Sale 10b5-1 | −5,840 | $110.29 | $644K | 700 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Option exercise · Stock Option (right to buy) 10b5-1 | −19,384 | $8.65 | $168K | 48,974 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Option exercise · Stock Option (right to buy) 10b5-1 | −6,968 | $11.55 | $80K | 4,063 |
| 2026-09-17 | Lynch Thomas P. See Remarks | Option exercise · Stock Option (right to buy) 10b5-1 | −2,920 | $17.12 | $50K | 5,417 |
Page 6 of 32 · 639 trades